Mark Douglas

3.3k total citations
31 papers, 1.9k citations indexed

About

Mark Douglas is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Mark Douglas has authored 31 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in Mark Douglas's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (9 papers) and Combustion and flame dynamics (4 papers). Mark Douglas is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (9 papers) and Combustion and flame dynamics (4 papers). Mark Douglas collaborates with scholars based in United States, Canada and United Kingdom. Mark Douglas's co-authors include Eric Croiset, Yewen Tan, K V Thambimuthu, Diksha Singh, Peter Douglas, E. H. Chui, Kerstin Allen, Jennifer Sweeney, Patrick Kelly and Steven M. Horwitz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Mark Douglas

30 papers receiving 1.8k citations

Peers

Countries citing papers authored by Mark Douglas

Since Specialization

Citations

This map shows the geographic impact of Mark Douglas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Douglas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Douglas more than expected).

Fields of papers citing papers by Mark Douglas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Douglas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Douglas. The network helps show where Mark Douglas may publish in the future.

Co-authorship network of co-authors of Mark Douglas

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Douglas. A scholar is included among the top collaborators of Mark Douglas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Douglas. Mark Douglas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study 2018 ·American Journal of Hematology ·Ian W. Flinn, Manish R. Patel, Yasuhiro Oki, Steven M. Horwitz, (unknown), Kerstin Allen, Mark Douglas, Howard M. Stern, Jennifer Sweeney, (unknown), Patrick Kelly, Virginia Kelly, Brad S. Kahl	26
2	Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study 2018 ·American Journal of Hematology ·Susan O’Brien, Manish R. Patel, Brad S. Kahl, Steven M. Horwitz, Francine M. Foss, Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Kerstin Allen, L. Kerrie, Mark Douglas, Howard M. Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Ian W. Flinn	48
3	Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies 2017 ·Blood ·Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, (unknown), Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz	183
4	Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma 2017 ·Blood ·Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison J. Moskowitz, Megan N. Perez, Patricia L. Myskowski, Adam Officer, Jacob D. Jaffe, Sara Morrow, Kerstin Allen, Mark Douglas, Howard M. Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David T. Weaver, Francine M. Foss, David M. Weinstock	204
5	Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199) 2016 ·Leukemia ·Viralkumar Patel, Kumudha Balakrishnan, Mark Douglas, Thomas T. Tibbitts, Ethan Xu, Jeffery L. Kutok, Mark Ayers, Aloke Sarkar, Renato Guerrieri, William G. Wierda, S O'Brien, Nitin Jain, Howard M. Stern, Varsha Gandhi	52
6	Abstract B032: The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment 2016 ·Cancer Immunology Research ·Matthew Rausch, Jeremy H. Tchaicha, Thomas T. Tibbitts, Olivier De Henau, Sujata Sharma, Melissa Pink, (unknown), Jennifer Proctor, Mark Douglas, Howard M. Stern, Taha Merghoub, Jedd D. Wolchok, Karen McGovern, Jeff Kutok, David A. Winkler	3
7	Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor. 2015 ·Journal of Clinical Oncology ·Mark Douglas, Kerstin Allen, Jennifer Sweeney, Susan O’Brien, Ian W. Flinn, Steven M. Horwitz, John C. Byrd, Manish R. Patel, Brad S. Kahl, Francine M. Foss, Pierluigi Porcu, Virginia Kelly, Howard M. Stern	2
8	Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL. 2015 ·Journal of Clinical Oncology ·Manish R. Patel, Susan O’Brien, L. Kerrie, Kerry White, Mark Douglas, Kerstin Allen, Jeffrey L. Kutok, Jennifer Sweeney, Virginia Kelly, Ian W. Flinn, John C. Byrd, Howard M. Stern	9
9	HSP90 Inhibition Enhances Antimitotic Drug-Induced Mitotic Arrest and Cell Death in Preclinical Models of Non-Small Cell Lung Cancer 2014 ·PLoS ONE ·Brenda O’Connell, Katie O’Callaghan, Bonnie Tillotson, Mark Douglas, Nafeeza Hafeez, Kip A. West, Howard M. Stern, Janid A. Ali, Paul S. Changelian, Christian Fritz, Vito J. Palombella, Karen McGovern, Jeffery L. Kutok	14
10	Abstract 1891: Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119. 2013 ·Cancer Research ·Erin Brophy, James Conley, Patrick J. O’Hearn, Mark Douglas, (unknown), (unknown), (unknown), Andrew A. Wylie, Thomas T. Tibbitts, Gregg F. Keaney, Lawrence Chan, Adilah Bahadoor, (unknown), Marta Nevalainen, Alfredo Castro, Vito J. Palombella, Massimo Loda, Stéphane Peluso	5
11	Treatment With The Potent PI3K-δ,γ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma 2013 ·Blood ·Mark Douglas, (unknown), (unknown), Kerstin Allen, Brad S. Kahl, Steven M. Horwitz, Ian W. Flinn, Patrick Kelly, Howard M. Stern	3
12	Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC) 2012 ·Cancer Research ·Dejan Juric, Guillem Argilés, (unknown), (unknown), Cristina Saura, Cornelia Quadt, Mark Douglas, David Demanse, Stefan Buck, José Baselga	28
13	Residential Total Energy System Installation at the Canadian Centre for Housing Technology 2008 ·(unknown), Mark Douglas, (unknown), Libing Yang, (unknown), (unknown), M. C. Swinton	4
14	Mercury removal from coal combustion by Fenton reactions. Paper B: Pilot-scale tests 2007 ·Fuel ·Yewen Tan, Dennis Y. Lu, Edward J. Anthony, (unknown), (unknown), Mark Douglas	26
15	Residential Total Energy System Testing at the Canadian Centre for Housing Technology 2007 ·Libing Yang, Mark Douglas, (unknown), (unknown), (unknown), (unknown), M. C. Swinton	5
16	An investigation of mercury distribution and speciation during coal combustion 2004 ·Fuel ·Yewen Tan, (unknown), (unknown), Mark Douglas	49
17	Techno-economic study of CO2 capture from an existing coal-fired power plant: MEA scrubbing vs. O2/CO2 recycle combustion 2003 ·Energy Conversion and Management ·Diksha Singh, Eric Croiset, Peter Douglas, Mark Douglas	438
18	CO2 capture using oxygen enhanced combustion strategies for natural gas power plants 2002 ·Fuel ·Yewen Tan, Mark Douglas, K V Thambimuthu	97
19	Combustion of paper deinking solids in a pilot-scale fluidized bed 1994 ·TSpace ·Mark Douglas, (unknown), (unknown), (unknown), Honghi Tran	6
20	Characterization of deinking sludge and its ashed residue 1994 ·TSpace ·(unknown), Honghi Tran, (unknown), Mark Douglas	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact